Introduction
The p53 tumor suppressor gene functions through induction of growth arrest or apoptosis in response to stress or genomic damage (1) . About 500/o of tumors carry p53 mutations (2) , suggesting that presence of a functional p53 pathway is incompatible with tumor growth. Tumors without p53 mutation may contain an impaired p53 pathway due to alternative mechanisms, such as overexpression of the MDM2 p53 level is due to prolonged half-life and is associated with an increase in p53 transcriptional activity, growth inhibition, or apoptosis. Inhibition of MDM2 expression is also sufficient to induce nuclear p53 accumulation in several cell lines with cytoplasmic p53. Conclusions: The MDM2 negative feedback loop is important for maintenance of p53 at a low level by promoting p53 degradation. Nuclear export and degradation by MDM2 may contribute to the p53 nuclear exclusion phenotype. Inhibition of MDM2 expression can effectively activate p53 in most tumor types, including those without MDM2 overexpression, and may have broad anti-tumor potential.
oncogene (3, 4) . p53 is an important mediator for the anti-cancer effects of many chemotherapeutic agents and ionizing irradiation (5) . Therefore, development of methods to activate p53 in tumor cells will shed light on the mechanism of p53 regulation and provide a potential new anticancer strategy.
The MDM2 oncogene was first cloned as an amplified gene on a murine double-minute chromosome (6) . Overexpression of MDM2 in cells increases the tumorigenic potential (6) and can cooperate with an activated ras oncogene to attain full transformation (7) . The MDM2 gene is amplified or overexpressed in about 40-60% of human osteogenic sarcomas and about 30% of soft-tissue sarcomas (3, 4) , implicating its role in the development of these malignancies. An important function of MDM2 is to bind to and inhibit the p53 tumor suppressor (8) . MDM2 can also promote degradation of p53 through a ubiquitin-dependent proteolytic pathway by acting as a ubiquitin ligase E3 (9) (10) (11) . p53 activates MDM2 expression at the level of transcription (12, 13) , suggesting that MDM2 can function as a negative feedback regulator of p53. Experiments using MDM2 knockout mice confirmed that an important function of MDM2 is to negatively regulate p53 (14, 15) . Recently, it was demonstrated that introduction of antibody 3G5 (16) , or an engineered protein that can inhibit MDM2-p53 binding, resulted in stimulation of p53 activity and accumulation of p53 in MCF-7 and T22 cells (17) . Therefore, MDM2 may have a constitutive role in promoting p53 turnover.
We previously identified a phosphorothioate antisense oligonucleotide against human MDM2. Inhibition of MDM2 expression in a tumor cell line (JAR) with MDM2 amplification resulted in activation of p53 and apoptosis. The MDM2 antisense oligonucleotide also enhanced the ability of a DNA damaging agent (camptothecin) to induce p53 in a synergistic fashion (18) , suggesting that the MDM2 feedback loop may limit the magnitude of p53 activation during a DNA-damage response. Therefore, inhibition of MDM2 expression may have therapeutic potential against human tumors expressing wild-type p53. However, many questions remain to be addressed, i.e., the effects of inhibiting MDM2 expression in tumors with different p53 mutation status, level, localization, stability, and MDM2 level. Furthermore, oligonucleotides identified in a primary screen is unlikely to be optimal.
In this study, we have developed a significantly improved MDM2 antisense phosphorothioate oligodeoxynucleotide that is a potent activator of p53. Inhibition of MDM2 expression in a large panel of human tumor cell lines using this oligonucleotide revealed that MDM2 is widely involved in suppressing the accumulation of p53. Therefore, inhibition of MDM2 expression is a powerful method for activating p53 by inducing p53 accumulation in the absence of DNA damage.
Materials and Methods
Synthesis of Oligodeoxynucleotides Phosphorothioate oligodeoxynucleotides were synthesized using ,B-cyanoethyl phosphoramidite chemistry on an automated synthesizer (Expedite 8909, Perceptive Biosystems, Framingham, MA) and purified by preparative reversephase high-performance liquid chromatography. Seven 20-mer phosphorothioate antisense oligodeoxynucleotides (AS 1-AS7) were synthesized for this screen (Fig. 1) The results showed that several of the secondary oligonucleotides were more effective than AS in causing activation of p53 (Fig. iB ). An oligonucleotide AS2 was the most potent of this group and was chosen for further characterization. AS2 was 5-fold more efficient than AS in MCF-7 cells (Fig. iB) and 2-fold more efficient than AS in JAR cells (not shown) at a concentration of 50 nM. The effect of AS2 is sequencespecific. Introduction of two or four nucleotide mismatches into the sequence significantly inhibited its ability to activate p53 (Fig. 1C) . Treatment of JAR cells with AS2 inhibited MDM2 protein expression in a sequence-dependent and dose-dependent fashion (Fig. ID) , suggesting that its ability to activate p53 is due to specific inhibition of MDM2 expression. Consistent with its increased ability to activate p53, AS2 is more efficient in inhibiting MDM2 expression (IC50: -25 nM, Fig. ID (Fig. 1) prompted us to further examine its effect on p53. MCF-7 cells predominantly contain a cytoplasmic form of p53 (20) and displayed a predominantly cytoplasmic fluorescence when stained using anti-p53 monoclonal antibody Pabl801. After treatment with 200 nM AS2 for 20 hr, many MCF-7 cells show intense nuclear p53 staining (Fig. 3) . The parent AS oligonucleotide also showed a similar but weaker ability to induce p53 accumulation (not shown), and the control oligonucleotide K did not induce p53 (Fig. 3) . This suggests that MDM2 plays an important role in inhibiting the accumulation of nuclear p53 in this cell line. Because there is an increase in total p53 after AS2 treatment (see below in Fig. 4) , and there is not an obvious loss of cytoplasmic p53 staining in cells accumulating nuclear p53, the results suggest that MDM2 normally promotes the degradation of nuclear p53 in MCF-7 cells.
To determine whether MDM2 also exhibits a similar role in other tumors containing cytoplasmic p53, the neuroblastoma cell line SK-N-SH was tested. Neuroblastomas rarely have p53 mutations but often contain p53 in the cytoplasm. SK-N-SH cells express cytoplasmic wild-type p53 and exhibit a reduced ability to undergo cell cycle arrest after DNA damage (21, 22 Figure 3 and summarized in Fig. 6 ). In these cases, cells rounded up, displayed membrane ruffling and blebbing characteristic of apoptosis, and detached from the culture surface. Staining of nuclear DNA also showed shrinkage and fragmentation of nuclei (Fig. 6B) . Thus, it appears that the level of p53 activation achieved by treatment with AS2 can be sufficient to induce cell death through apoptosis in some cell lines examined. Some of the tumor cell lines (MCF-7, SJSA, A549, A174) as well as two nontransformed cell lines (WI-38 and Jekin) showed little cell death after a 20-hr AS2 treatment. Since p53 activation can lead to apoptosis or cell cycle arrest, dependent on the level of p53 and the status of the cell, several of these cell lines were further tested for growth arrest by AS2. Cells were treated with AS2 or control oligonucleotides for 20 hr, and DNA synthesis was quantitated by BrdU incorporation. The number of viable cells was determined by incubation with the MTS reagent. The results show that in cell lines that do not undergo significant apoptosis after AS2 treatment, the rate of DNA synthesis is reduced (Fig. 7) . This effect is weaker with a 4-bp mismatch control oligonucleotide and is not observed with the unrelated oligonucleotide K. In contrast, the p53-null cell lines H1299 (human) and 10(1) (mouse) (23) did not undergo significant growth inhibition. Therefore induction of p53 by inhibition of MDM2 can lead to growth arrest or apoptosis.
MDM2-Mediated Degradation of p53 Is Inefficient in Two Choriocarcinoma Cell Lines
The results presented in Table 1 also reproduce our previous observation that in JAR and JEG-3 cells with high levels of p53 and MDM2, inhibition of MDM2 expression did not result in a significant increase in p53 level. These notable exceptions suggest that the ability of MDM2 to promote p53 degradation may be suppressed in choriocarcinoma cell lines, which predict that p53 is not actively degraded through the ubiquitin-dependent proteasome pathway in these cells.
To test this possibility, JAR and JEG-3 cells were treated with the proteasome inhibitor MG132, which blocks ubiquitin-dependent degradation of proteins (24) . PA-1 cells that have highly inducible p53 after MDM2 antisense 29 
Control treated AS2 treated
Control treated AS2 treated treatment were used as a control. Treatment with 10 ,uM of MG132 for 3-6 hr resulted in an over 10-fold increase in MDM2 in all three cell lines (Fig. 8) , confirming a previous report that MDM2 is degraded through the ubiquitin-dependent proteasome pathway (25) . MG132 only . Cytoplasmic accumulation of wild-type p53 is frequently observed in breast tumors and neuroblastomas (21, 31 ) , and may represent an alternative mechanism of p53 inactivation. A model of cytoplasmic p53 sequestration through inhibition of nuclear translocation has been proposed to explain this phenomenon (32) . Our results with MCF-7 and SK-N-SH cells suggest that MDM2 plays an important role in preventing nuclear p53 accumulation in these cells. Inhibition of MDM2 expression can lead to accumulation of nuclear p53 and increase in total cellular p53. Recent findings suggest that MDM2 can promote p53 degradation (9, 10) , and this activity is dependent on the nuclear export function of MDM2 (33) . Collectively, these results suggest that the cytoplasmic p53 phenotype reflects a dynamic process in which p53 enters the nucleus, binds to MDM2, exits the nucleus as a p53-MDM2 complex, and is degraded or sequestered into cytoplasmic particles. Other experimental approaches are needed to further elucidate this phenomenon.
Two choriocarcinoma cell lines (JAR, JEG-3) show an interesting deviation from most cell lines. Consistent with the observation that they have high levels of MDM2 and stable wild-type p53 (26) , inhibition of MDM2 expression or inhibition of proteasome function do not lead to significant accumulation of p53. These results are consistent with the notion that in JAR and JEG-3 cells, MDM2 inhibits p53 mainly through formation of inactive complexes, not promotion of p53 turnover. Whether this is characteristic of trophoblastic tumors and reflects a defect (e.g., lack of a co-factor, point mutation in MDM2) or an active regulation of this degradation pathway remains to be investigated.
Our results demonstrate that inhibition of MDM2 expression is a highly efficient method of activating p53 without causing DNA damage, and may have therapeutic potential against a wide range of tumors. However, systemic inhibition of MDM2 expression will also activate p53 in normal cells that are undergoing rapid proliferation, such as hematopoietic cells and mucosal epithelial cells. These cells are sensitive to p53-induced apoptosis after DNA damaging treatments, as indicated by experiments using p53 knockout mice (34) (35) (36) (37) . Therefore, the anti-tumor specificity and general toxicity of MDM2 inhibitors require further study.
Inhibition of MDM2 activates p53 uniformly and much more efficiently than many DNAdamaging chemotherapy agents (camptothecin, adriamycin, cisplatin, etoposide, fluorouracil, and methotrexate, unpublished results, J. Chen) . The ability of these drugs to activate p53 is dependent on cellular uptake, target sensitivity, and the integrity of signal transduction pathways to p53 in individual tumors. Inhibition of MDM2 expression can bypass these deficiencies and achieve strong p53 activation in a broad range of tumor types; thus it may be useful to augment drugs that are inefficient in activating p53 and complement drugs that do not activate p53.
The results of this study suggest that MDM2 is a useful drug target in many tumor types, even when it is not a causative factor during tumor development. Many types of tumors have frequencies of 20-30% (2). Therefore, inhibitors of MDM2 may be useful for the majority of such cases. With the recent approval of the first antisense oligonucleotide-based drug, Fomivirsen, for the treatment of CMV retinitis in AIDS patients, it is evident that this type of compound also has a therapeutic potential. The AS2 oligonucleotide provides a starting point for chemical improvements and further investigation of its anti-tumor potential.
